The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." https://harmonyymkh028698.get-blogging.com/40604170/elite-stakeholder-pharma-hazardous-wager